title: [Combination radiotherapy and chemotherapy in the treatment of locally advanced adenocarcinoma of the pancreas. Experiences of the Gustave Roussy Institute].
abstract: Non-resectable pancreatic adenocarcinomas (PA) are of poor prognosis with median survival of 4-6 months. Radiotherapy (RT) and chemotherapy (CT) association are potential palliative treatments recently investigated. We have tested such an association in a pilot study. Twelve patients (pts) with non-resectable PA and localized tumors were treated by 2 cycles of CT (5-FU + adriamycin + cisplatinum) and then 2 or 3 split courses of RT (20 Gy/12 days and 8 fractions with a 16 day interval). CT was reintroduced, if initially active, for 3 cycles. Results were: 3 CR (11+, 13+, 16 months) for a response rate of 25%, 1 MR (4 months) and 5 stabilizations longer than 6 months. The 1 year survival was 56 +/- 15% with no patient surviving longer than 2 years. Tolerance was acceptable for RT and toxicity with CT was digestive (grade II) for all pts, leucopenia grade III for 3 pts and thrombopenia grade II for 2 pts. Two pts experienced digestive hemorrhage for anastomatic ulceration, responsible for death in one case. This pilot study confirms the transient efficacy of RT + CT association for non-resectable PA. However, the toxicity and treatment duration lead us to recommend other studies of less toxic association before initiation of randomized trials.
authors.affiliation: Département de radiothérapie, Institut Gustave-Roussy, Villejuif, France.
authors.forename: F
authors.initials: F
authors.lastname: Eschwege
authors.forename: P
authors.initials: P
authors.lastname: Rougier
authors.forename: S
authors.initials: S
authors.lastname: Delanian
authors.forename: L
authors.initials: L
authors.lastname: Abensour
authors.forename: J P
authors.initials: JP
authors.lastname: Droz
authors.forename: P
authors.initials: P
authors.lastname: Wibault
authors.forename: A
authors.initials: A
authors.lastname: Lusinchi
authors.forename: P
authors.initials: P
authors.lastname: Lasser
mesh_terms: D000206:Actuarial Analysis; D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D004317:Doxorubicin; D002945:Cisplatin; D005472:Fluorouracil
vernacular_title: Association radio-chimiothérapie pour le traitement des adénocarcinomes du pancréas (AP) localement avancés. Expérience de l'IGR.